Molecular profiles of screen detected vs. symptomatic breast cancer and their impact on survival: Results from a clinical series

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Crispo, Anna ^a   Barba, Maddalena ^b   D'Aiuto, Giuseppe ^a   De Laurentiis, Michelino ^a   Grimaldi, Maria ^a   Rinaldo, Massimo ^a   Caolo, Giuseppina ^a   D'Aiuto, Massimiliano ^a   Capasso, Immacolata ^a   Esposito, Emanuela ^a   Amore, Alfonso ^a   Di Bonito, Maurizio ^a   Botti, Gerardo ^a   Montella, Maurizio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Breast cancer; Mode of detection; Molecular categories; Screening; Survival outcomes

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SCREENING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; OVERALL SURVIVAL; SYMPTOM ASSESSMENT; TUMOR VOLUME;

ADULT; AGED; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84872103821     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-15     Document Type: Article

References (31)

1. Perry N, Broeders M, de Wolf C, Törnberg S, Holland R, von Karsa L. European Guidelines for Quality Assurance in Breast Cancer Screening and Diagnosis 2006, Luxembourg: Office for Official Publications of the European Communities.
2. Breast Cancer Screening 2002, Lyon, France: IARC Press, Vainio H, Bianchini F, IARC Handbooks of Cancer Prevention; Vol 7.
3. Ministry of Health Recommendations for oncologic screenings: prevention of breast cancer, cervical cancer and colorectal cancer 2006, Ministry of Health.
4. Smith R. International programmes for the detection of breast cancer. Salud Publica Mex 2011, 53(5):394-404.
5. Pálka I, Kelemen G, Ormándi K, Lázár G, Nyári T, Thurzó L, et al. Tumor characteristics in screen-detected and symptomatic breast cancers. Pathol Oncol Res 2008, 14:161-167. 10.1007/s12253-008-9010-7, 18347932.
6. Shen Y, Yang Y, Inoue LY, Munsell MF, Miller AB, Berry DA. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst 2005, 97:1195-1203. 10.1093/jnci/dji239, 16106024.
7. Joensuu H, Lehtimäki, Holli K, Elomaa L, Turpeenniemi-Hujanen T, Kataja V, et al. Risk for distant recurrence of breast cancer detected by mammography screening or other methods. JAMA 2004, 292:1064-1073. 10.1001/jama.292.9.1064, 15339900.
8. Wishart GC, Greenberg D, Britton PD, Chou P, Brown CH, Purushotham AD, et al. Screen-detected vs symptomatic breast cancer: is improved survival due to stage migration alone?. Br J Cancer 2008, 98:1741-1744. 10.1038/sj.bjc.6604368, 2410118, 18506175.
9. Mook S, Veer LJ V, Rutgers EJ, Ravdin PM, van de Velde AO, van Leeuwen FE, et al. Independent prognostic value of screen detection in invasive breast cancer. J Natl Cancer Inst 2011, 103:585-597. 10.1093/jnci/djr043, 21350218.
10. Perou CM, Sørlie T, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406(6797):747-752. 17, 10.1038/35021093, 10963602.
11. Dawson SJ, Provenzano E, Caldas C. Triple negative breast cancers: clinical and prognostic implications. Eur J Cancer 2009, 45(Suppl 1):27-40.
12. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10:5367-5374. 10.1158/1078-0432.CCR-04-0220, 15328174.
13. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer Epidemiol Biomarkers Prev 2007, 109:25-32.
14. Crispo A, Montella M, Barba M, Schittulli F, De Marco MR, Grimaldi M, Quaranta M, Serravezza G, Savastano C, Botti G, La Vecchia C, D'Aiuto G. Association between mode of breast cancer detection and diagnosis delay. Breast 2009, 18(6):382-386. 10.1016/j.breast.2009.10.001, 19879761.
15. Meier EKP. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958, 53:457-481.
16. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc 1972, 135:185-206.
17. Cox D. Regression models and life tables (with discussion). J R Stat Soc 1972, 4:187-220.
18. Anderson T, Alexander FE, Lamb J, Smith A, Forrest A. Pathology characteristics that optimize outcome prediction of a breast screening trial. Br J Cancer 2000, 83(4):487-492. 10.1054/bjoc.2000.1286, 2374653, 10945496.
19. Allgood PC, Duffy S, Kearins O, O'Sullivan E, Tappenden N, Wallis MG, Lawrence G. Explaining the difference in prognosis between screen-detected and symptomatic breast cancers. Br J Cancer 2011, 104(11):1680-1685. 10.1038/bjc.2011.144, 3111158, 21540862.
20. Biesheuvel C, Czene K, Orgeás CC, Hall P. The role of mammography screening attendance and detection mode in predicting breast cancer survival-is there added prognostic value?. Cancer Epidemiol 2011, 35(6):545-550. Epub 2011 Apr 5, 10.1016/j.canep.2011.02.008, 21470933.
21. Hutchison GB, Shapiro S. Lead time gained by diagnostic screening for breast cancer. J Natl Cancer Inst 1968, 41(3):665-681.
22. Shapiro S, Goldberg J, Hutchison GB. Lead time in breast cancer detection and implications for periodicity of screening. Am J Epidemiol 1974, 100(5):357-366.
23. Dawson SJ, Duffy S, Blows FM, Driver KE, Provenzano E, LeQuesne J, Greenberg DC, Pharoah P, Caldas C, Wishart GC. Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival. Br J Cancer 2009, 101(8):1338-1344. 10.1038/sj.bjc.6605317, 2768460, 19773756.
24. Pronzato P, Mustacchi G, De Matteis A, Di Costanzo F, Rulli E, Floriani I, Cazzaniga ME. Biological characteristics and medical treatment of breast cancer in young women-a featured population: results from the NORA study. Int J Breast Cancer 2011,
25. Kim J, Sekyung L, SooYoun B, et al. Comparison between screen-detected and symptomatic breast cancers according to molecular subtypes. Breast Cancer Res Treat 2012, 131(2):527-540. 10.1007/s10549-011-1836-0, 22042364.
26. Wang Y, Yin Q, Yu Q, Zhang J, Liu Z, Wang S, Lv S, Niu Y. A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments. Breast Cancer Res Treat 2011, 130(2):489-498. 10.1007/s10549-011-1709-6, 21837481.
27. Voduc KD, Cheang M, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 2010, 28(10):1684-1691. 10.1200/JCO.2009.24.9284, 20194857.
28. Dawood S, Hu R, Homes MD, Collins LC, Schnitt SJ, Connolly J, Colditz GA, Tamimi RM. Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study. Breast Cancer Res Treat 2011, 126(1):185-192. 10.1007/s10549-010-1113-7, 3026074, 20711652.
29. Sihto H, Lundin J, Lehtimaki T, Sarlomo-Rikala M, Butzow R, Holli K, Sailas L, Kataja V, Lundin M, Turpeenniemi-Hujanen T, Isola J, Heikkila P, Joensuu H. Molecular subtypes of breast cancers detected in mammography screening and outside of screening. Clin Cancer Res 2008, 14:4103-4110. 10.1158/1078-0432.CCR-07-5003, 18593987.
30. de Mutsert R, Jager K, Zoccali C, Dekker FW. The effect of joint exposures: examining the presence of interaction. Kidney Int 2009, 75(7):677-681. 10.1038/ki.2008.645, 19190674.
31. Norman SA, Localio A, Zhou L, Bernstein L, Coates RJ, Flagg EW, Marchbanks PA, Malone KE, Weiss LK, Lee NC, Nadel MR. Validation of self-reported screening mammography histories among women with and without breast cancer. Am J Epidemiol 2003, 158(3):264-271. 10.1093/aje/kwg136, 12882949.